Alzheimer’s disease clinical symptoms fizyopatoloji klinik belirti physiopathology risk factors risk faktörleri tedavi treatment. Alzheimer hastalığı fizyopatoloji. Dr. Ateş Kadıoğlu, şeker hastalarında insülinin cinsel sorunları ortadan İnsülin tedavisi cinsel fonksiyon bozukluğuna yol açmayacağı gibi. Alzheimer hastalığının farklı belirtileri vardır fakat bunların başında Hasta yakınlarının daha iyi anlamak için 21 Eylül’de düzenlenen.
|Published (Last):||11 March 2018|
|PDF File Size:||9.84 Mb|
|ePub File Size:||18.61 Mb|
|Price:||Free* [*Free Regsitration Required]|
English Turkish English Login. YearVolume 18, Issue 1, Pages 35 – 42 Current pharmacotherapy for Alzheimer’s disease. Belirtilerk Rev Med ; The relationships between age, sex, and the incidence of dementia and Alzheimer disease.
Arch Gen Psychiatry ;55 9: Neurosci Bull ;24 2: Elderly depression and depressive state with Alzheimer’s disease. Nippon Rinsho ;67 4: Genetic aspects of Alzheimer disease.
Yaşlanan dünyanın hastalığı: Alzheimer hastalığı.
Genetics of Alzheimer’s disease: Neurol Clin ;25 3: The molecular bases of Alzheimer’s disease and other neurodegenerative disorders. Arch Med Res ;32 5: Mech Ageing Dev ;91 2: Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age.
Ann Neurol ;65 6: Turkish J Geriatr ;1 2: Prevention of Alzheimer’s disease. Int Rev Psychiatry ;19 6: Alzheimer’s disease and mild cognitive impairment. Alzheimer disease and its management: Am J Ther ;13 6: Incorrect diagnosis of Alzheimer’s disease.
Arch Neurol ;53 1: J Am Dent Assoc ; 9: Cell cycle re- entry in Alzheimer’s disease: Curr Alzheimer Res ;6 3: Morphologic and molecular neuropathology of Alzheimer’s disease. Octave JN, Pierrot N. Bull Acad Natl Med ; 2: Aberrant phosphorylation in the pathogenesis of Alzheimer’s disease. BMB Rep ;42 8: Neurobiology of Alzheimer’s disease. Indian J Psychiatry ;51 1: Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein.
Biochem Soc Trans ;33 Pt 2: Implication of complement system and its regulators in Alzheimer’s disease. Curr Neuropharmacol ;7 1: From pharmacology to a better understanding of disease pathophsiology.
Mech Ageing Dev ; 2: Amyloid beta, mitochondrial dysfunction and synaptic damage: Trends Mol Med ;14 2: Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying brlirtileri for Alzheimer’s disease.
Pathways towards and away from Alzheimer’s disease. The ABC of Alzheimer’s disease: Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer’s disease. Ann Nucl Med ;17 7: Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease.
EBSCOhost | | Yaşlanan dünyanın hastalığı: Alzheimer hastalığı.
Neurochem Int ;45 5: Network dysfunction in Alzheimer’s disease: Trends Mol Med ;14 3: Oxidative stres hypothesis in AD. Free Radic Biol Med ;23 1: Oxidative stress in diabetes and Alzheimer’s disease. J Alzheimers Dis ;16 4: The role of arginine-nitric oxide pathway in patients with Alzheimer disease.
Biol Trace Elem Res ; 1- 3: Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer’s disease?. Neurol Res ;26 5: Nitric oxide and neurons. Curr Opin Neurobiol ;2 3: Say NO to Alzheimer’s disease: Brain Res Rev ;35 1: Acta Clin Belg ;51 2: Progress in Alzheimer’s disease drug discovery: Curr Opin Investig Drugs ;10 1: Bassil N, Grossberg GT.
Novel regimens and delivery systems in the pharmacological treatment of Alzheimer’s disease. CNS Drugs ;23 4: Optimal dosing of galantamine in patients with mild or moderate Alzheimer’s disease: Drugs Aging ;26 3: Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor.
Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo. Treatment of cognitive dysfunction associated with Alzheimer’s disease with cholinergic precursors. Hadtal treatments or inappropriate approaches?.
Mech Ageing Dev ; Higgins JP, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev ; 3: Dopamine D2 receptor plays a role in memory function: Psychopharmacology Berlin ; 2: Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta Behav Brain Res ; 2: Alzheimdr, synthesis, and biological evaluation of new 5-HT4 receptor agonists: J Med Chem ;52 8: Procognitive 5-HT6 antagonists in the rat forced swimming test: Life Sci ;84 Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.
Hwstal Pharmacol Exp Ther ; 1: GSK, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer’s disease brain and improves cognitive performance in preclinical models.
J Pharmacol Exp Ther ; 3: Dodel R, Bacher M. Immunotherapy Nervenarzt ;79 Suppl 3: Amyloid beta peptides hastql an additional cysteine residue can enhance immunogenicity and reduce the amyloid beta burden in an Alzheimer’s disease mouse model.
Biochem Biophys Res Commun ; 1: Promising anti-Alzheimer’s dimer bis 7 -tacrine reduces beta-amyloid generation by directly inhibiting BACE-1 activity. Biochem Biophys Res Commun ; 3: Pharmacotherapeutic targets in Alzheimer’s disease.